Equities research analysts expect that Proteostasis Therapeutics Inc (NASDAQ:PTI) will post ($0.58) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Proteostasis Therapeutics’ earnings, with estimates ranging from ($0.61) to ($0.55). Proteostasis Therapeutics posted earnings per share of ($0.87) in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The company is scheduled to announce its next quarterly earnings report on Friday, May 12th.
On average, analysts expect that Proteostasis Therapeutics will report full year earnings of ($2.16) per share for the current fiscal year, with EPS estimates ranging from ($2.46) to ($1.77). For the next year, analysts expect that the firm will post earnings of ($2.19) per share, with EPS estimates ranging from ($2.53) to ($1.89). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Proteostasis Therapeutics.
PTI has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Proteostasis Therapeutics in a research note on Tuesday, January 24th. Zacks Investment Research upgraded shares of Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 21st. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $13.00 target price on shares of Proteostasis Therapeutics in a research note on Sunday, April 2nd.
In related news, insider Fmr Llc sold 28,000 shares of the firm’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $14.60, for a total value of $408,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 257,300 shares of company stock valued at $3,451,694 over the last quarter. 29.50% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the stock. NEA Management Company LLC increased its stake in shares of Proteostasis Therapeutics by 14.9% in the third quarter. NEA Management Company LLC now owns 3,556,778 shares of the company’s stock valued at $55,450,000 after buying an additional 461,538 shares during the period. Hillhouse Capital Management Ltd. bought a new stake in shares of Proteostasis Therapeutics during the third quarter valued at about $11,907,000. Rock Springs Capital Management LP increased its stake in shares of Proteostasis Therapeutics by 8.4% in the third quarter. Rock Springs Capital Management LP now owns 450,000 shares of the company’s stock valued at $7,016,000 after buying an additional 35,000 shares during the period. Marshall Wace LLP increased its stake in shares of Proteostasis Therapeutics by 32.2% in the fourth quarter. Marshall Wace LLP now owns 442,836 shares of the company’s stock valued at $5,429,000 after buying an additional 107,866 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Proteostasis Therapeutics by 174.7% in the third quarter. JPMorgan Chase & Co. now owns 172,650 shares of the company’s stock valued at $2,692,000 after buying an additional 109,800 shares during the period. Institutional investors and hedge funds own 67.71% of the company’s stock.
Shares of Proteostasis Therapeutics (NASDAQ:PTI) traded down 1.77% on Thursday, reaching $6.10. The company’s stock had a trading volume of 269,878 shares. The company has a 50 day moving average price of $10.25 and a 200 day moving average price of $11.95. Proteostasis Therapeutics has a 52-week low of $5.85 and a 52-week high of $20.63. The company’s market cap is $152.65 million.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065409/brokerages-expect-proteostasis-therapeutics-inc-pti-will-post-earnings-of-0-58-per-share.html
Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.